NASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $6.22 -0.01 (-0.16%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.10▼$6.4250-Day Range$4.26▼$6.5952-Week Range$3.89▼$7.28Volume608,316 shsAverage Volume272,507 shsMarket Capitalization$260.31 millionP/E RatioN/ADividend YieldN/APrice Target$19.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zevra Therapeutics alerts: Email Address Zevra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside213.5% Upside$19.50 Price TargetShort InterestBearish7.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$140,340 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.57) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.68 out of 5 starsMedical Sector703rd out of 936 stocksPharmaceutical Preparations Industry328th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZevra Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Zevra Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.63% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 7.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVRA. Previous Next 3.3 News and Social Media Coverage News SentimentZevra Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Zevra Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for ZVRA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $140,340.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zevra Therapeutics are expected to grow in the coming year, from ($1.57) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Zevra Therapeutics Stock (NASDAQ:ZVRA)Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.Read More ZVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVRA Stock News HeadlinesJuly 18, 2024 | insidertrades.comInsider Buying: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO Acquires 2,000 Shares of StockJuly 17, 2024 | insidertrades.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Purchases $68,100.00 in StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | insidertrades.comJohn B. Bode Purchases 10,000 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) StockJuly 19, 2024 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO R. Laduane Clifton Purchases 2,000 SharesJuly 18, 2024 | americanbankingnews.comBrokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $19.50July 17, 2024 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Director Acquires $58,700.00 in StockJune 18, 2024 | prnewswire.comZevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 18, 2024 | globenewswire.comZevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersJune 3, 2024 | globenewswire.comZevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual MeetingMay 9, 2024 | finance.yahoo.comZevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | finance.yahoo.comZevra Therapeutics to Participate at Upcoming Investor EventsMay 9, 2024 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comZevra Therapeutics Inc (ZVRA) Q1 2024 Earnings: Misses EPS Estimates, Revenue Consistent with ...May 8, 2024 | investorplace.comZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comZevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRASee More Headlines Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZVRA CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$19.50 High Stock Price Target$25.00 Low Stock Price Target$15.00 Potential Upside/Downside+213.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,050,000.00 Net Margins-181.76% Pretax Margin-176.46% Return on Equity-82.55% Return on Assets-35.84% Debt Debt-to-Equity Ratio0.88 Current Ratio2.10 Quick Ratio2.10 Sales & Book Value Annual Sales$27.46 million Price / Sales9.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.71 per share Price / Book3.64Miscellaneous Outstanding Shares41,850,000Free Float40,849,000Market Cap$260.31 million OptionableOptionable Beta1.97 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Neil F. McFarlane (Age 51)President, CEO & Director Comp: $503.77kMs. Christal M. M. Mickle M.A. (Age 45)Co-Founder & Chief Development Officer Comp: $622.36kMr. R. LaDuane Clifton CPA (Age 52)CFO, Secretary & Treasurer Comp: $658.43kMr. Joshua M. Schafer M.B.A. (Age 52)Chief Commercial Officer & Executive VP of Business Development Comp: $766.07kDr. Sven Guenther Ph.D. (Age 52)Chief Scientific Officer Comp: $497.26kMs. Nichol L. OchsnerVice President of Investor Relations & Corporate CommunicationsDr. Christopher M. Lauderback Ph.D. (Age 49)Senior Vice President of Manufacturing Dr. Rene A. Braeckman Ph.D.Senior Vice President of Clinical DevelopmentDr. Daniel Gallo Ph.D.Senior Vice President of Medical Affairs & AdvocacyDr. Adrian Quartel FFPM (Age 63)M.D., Chief Medical Officer More ExecutivesKey CompetitorsBicycle TherapeuticsNASDAQ:BCYCAnaptysBioNASDAQ:ANABCentessa PharmaceuticalsNASDAQ:CNTACronos GroupNASDAQ:CRONMesoblastNASDAQ:MESOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 21,231 shares on 7/26/2024Ownership: 0.527%R. Laduane CliftonBought 2,000 shares on 7/17/2024Total: $13,540.00 ($6.77/share)Thomas AndersonBought 10,000 shares on 7/16/2024Total: $68,100.00 ($6.81/share)John B BodeBought 10,000 shares on 7/12/2024Total: $58,700.00 ($5.87/share)Jacobs Levy Equity Management Inc.Bought 17,557 shares on 5/16/2024Ownership: 0.083%View All Insider TransactionsView All Institutional Transactions ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $6.55 on January 1st, 2024. Since then, ZVRA shares have decreased by 5.0% and is now trading at $6.22. View the best growth stocks for 2024 here. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) released its earnings results on Wednesday, May, 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. The company had revenue of $3.43 million for the quarter, compared to the consensus estimate of $3.52 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 82.55% and a negative net margin of 181.76%. Who are Zevra Therapeutics' major shareholders? Top institutional shareholders of Zevra Therapeutics include Bank of New York Mellon Corp (0.53%). Insiders that own company stock include John B Bode, Thomas Anderson, Matthew R Plooster, Timothy J Sangiovanni, Joshua Schafer, Corey Michael Watton and Tamara A Seymour. View institutional ownership trends. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVRA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
